UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): ~~May~~June 1423, 2021 ~~(May 12, 2021)~~

MISONIX, INC.

(Exact name of Registrant as specified in its charter)

Delaware

001-10986

84-1856018

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification Number)

1938 New Highway, Farmingdale, New York		11735
(Address of Principal Executive Offices)		(Zip Code)

(631) 694-9555

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of exchange on which registered
Common Shares, $0.0001 par value		MSON		The Nasdaq Global Market

Item 5.0207. ~~Departure~~Submission of ~~Directors~~Matters orto ~~Certain~~a ~~Officers;~~Vote ~~Election~~ of ~~Directors;~~Security ~~Appointment of Certain Officers; Compensatory Arrangements of Certain Officers~~Holders.

~~Effective~~The ~~on May 12,~~ 2021, ~~the~~Annual ~~Board~~Meeting of ~~Directors~~Stockholders (the “~~Board~~Annual Meeting”) of Misonix, Inc. (the “Company”), ~~upon~~was ~~the~~held recommendation of the Nominating and Governance Committee, increased the size of the Board from four to five members and appointed Patrick J. Beyer to serve as a director. The Board has appointed Mr. Beyer to the Audit Committee and the Nominating and Governance Committee, and, as a result, Paul LaViolette will no longer serve on ~~the Audit Committee and Thomas M. Patton will no longer serve on the~~June ~~Nominating and Governance Committee~~23, ~~each effective on May 12,~~ 2021.

~~Mr.~~At ~~Beyer, who satisfies~~ the ~~independence~~Annual ~~requirements of the Nasdaq Stock Market and the Securities and Exchange Commission (the “SEC”) rules~~Meeting, ~~will serve for an initial term to expire concurrently with~~ the ~~terms~~stockholders of the ~~other members of the Board at the~~ Company’s 2021 annual meeting of stockholders, and until his successor is duly elected and qualified. Mr. Beyer, age 55, is President of International and Global Orthopedics for ConMed Corporation, a publicly held medical technology company.:

~~In connection~~(i) ~~with~~elected MrPatrick J. Beyer~~’s appointment to the Board~~, ~~and~~Michael ~~pursuant to the Company’s 2017 Equity Incentive Plan~~Koby, ~~as amended,~~Paul ~~the Board granted~~LaViolette, ~~effective~~Thomas ~~May~~M. ~~14,~~Patton ~~2021,~~and ~~Mr. Beyer~~Stavros anVizirgianakis ~~option~~ to ~~purchase~~serve ~~20,000~~as ~~shares~~directors of the Company’s; ~~common~~(ii) ~~stock~~approved, aton ana ~~exercise~~non-binding ~~price~~advisory ~~equal~~basis, to the ~~closing~~compensation ~~price per share~~ of the Company’s ~~common~~named ~~stock~~executive onofficers; ~~May,~~(iii) ~~14,~~approved ~~2021,~~ the ~~date~~ ofMisonix, ~~grant~~Inc. ~~The~~Employee ~~options~~Stock ~~will~~Purchase ~~vest~~Plan; asand to(iv) ~~25%~~ratified of the ~~award~~appointment ~~on each anniversary~~ of ~~the~~Deloitte ~~date~~& ofTouche ~~grant~~LLP ~~over~~as ~~a four year period, subject to Mr. Beyer’s continued service on~~ the ~~Board. Mr. Beyer’s compensation will be consistent with other non-employee members of the Board, which is described in the~~ Company’s ~~Proxy~~independent ~~Statement~~registered onpublic ~~Schedule~~accounting ~~14A~~firm ~~filed~~for ~~with~~ the ~~SEC~~fiscal onyear ~~May~~ending 26June 30, ~~2020,~~ ~~and as may be amended from time to time by the Board~~2021.

~~There are no arrangements or understandings between Mr~~1. ~~Beyer and any other persons pursuant to which Mr. Beyer was appointed as a director,~~ ~~and~~The ~~Mr.~~votes ~~Beyer~~cast isby ~~not~~stockholders awith ~~party~~respect to ~~any transaction with~~ the ~~Company~~election ~~reportable pursuant to Item 404(a)~~ of ~~Regulation~~directors ~~S-K~~were ~~under~~as ~~the Securities Act of 1933.~~follows:

Item 7.01. Regulation FD Disclosure.

	Votes		Votes		Broker
Director	“For”		Withheld		Non-Votes

Patrick J. Beyer		9,585,749		96,163		4,470,331

Michael Koby		8,649,559		1,032,353		4,470,331

Paul LaViolette		7,965,868		1,716,044		4,470,331

Thomas M. Patton		9,555,803		126,109		4,470,331

Stavros Vizirgianakis		9,632,108		49,804		4,470,331

On2. ~~May~~The ~~14,~~votes ~~2021,~~cast ~~the~~by ~~Company issued a press release announcing~~ the ~~appointment~~stockholders ofwith ~~Mr.~~respect ~~Beyer~~ to the ~~Board~~approval, ason ~~described~~a ~~under~~non-binding ~~Item 5.02~~advisory basis, ~~above.~~of Athe ~~copy~~compensation of the ~~press~~Company’s named ~~release~~executive isofficers ~~attached~~were as ~~Exhibit 99.1 to this Current Report.~~follows:

The information included in Exhibit 99.1 is being “furnished” and shall not be deemed “filed” for purposes of Section 18 of the U.S. Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be incorporated by reference in any filing under the U.S. Securities Act of 1933, as amended, or the Exchange Act.

Votes “For”	Votes “Against”	Abstentions	Broker Non-Votes

9,552,240	114,485	15,187	4,470,331

~~Item 9~~3.~~01.~~ The ~~Financial~~votes ~~Statements~~cast ~~and~~by ~~Exhibits~~the stockholders with respect to the approval of the Misonix, Inc. Employee Stock Purchase Plan were as follows:

(d) Exhibits

Votes “For”	Votes “Against”	Abstentions	Broker Non-Votes

9,669,566	6,812	5,534	4,470,331

Exhibit No.		Description
99.1		Press Release dated May 14, 2021
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

4. The votes cast by shareholders with respect to the ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2021 were as follows:

Votes “For”	Votes “Against”	Abstentions

14,136,178	5,262	10,803

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: May 14, 2021	MISONIX, INC.
Dated: June 23, 2021	MISONIX, INC.
	By:	/s/ Joseph P. Dwyer
		Joseph P. Dwyer Chief Financial Officer
		Joseph P. Dwyer
		Chief Financial Officer

Filing Compare · MISONIX INC